The US Food and Drug Administration (FDA) has approved the new drug application for Eisai Co Ltd’s in-house discovered and developed orexin receptor antagonist DAYVIGO (lemborexant). DAYVIGO was approved for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance in adults. In the United States, DAYVIGO will be commercially available in … Continue reading FDA Approves Orexin Receptor Antagonist for Insomnia